Drug Profile

Luvesilocin - Reunion Neurosciences

Alternative Names: RE-104

Latest Information Update: 26 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Reunion Neuroscience
Class Antidepressants; Behavioural disorder therapies; Small molecules
Mechanism of Action Serotonin 5-HT2A receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Adjustment disorders; Postnatal depression

Most Recent Events

23 Feb 2026 Luvesilocin receives Breakthrough Therapy status for Postnatal depression in USA
12 Jan 2026 Reunion Neuroscience plans a phase III trial for Postnatal depression later in 2026
12 Jan 2026 Reunion Neuroscience announces intention to submit NDA to FDA for Postnatal depression

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com